3.9 Article

Management of overweight and obese patients with coronary heart disease across Europe

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1097/HJR.0b013e328336a05f

Keywords

coronary heart disease; obesity; secondary prevention

Funding

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. GlaxoSmithKline
  4. Pfizer
  5. Sanofi-Aventis
  6. Servier
  7. Merck/Schering-Plough
  8. Novartis

Ask authors/readers for more resources

Aims Several studies have reported increasing obesity rates in the general population. Using data from the EUROASPIRE III survey, we investigated as to what extent the obesity epidemic affects the high priority group of coronary heart disease patients. Methods and results Data from 8924 patients, who had experienced a recent coronary acute event, from 22 countries in Europe participating in the EUROASPIRE III study were gathered in 2006- 2007. Eight centres had also participated in the earlier two EUROASPIRE surveys carried out in 1994- 1995 and 1999- 2000. In these eight centres, obesity prevalence in coronary patients had increased from 25 to 38% during the past decade. The most recent survey shows that obesity is more prevalent in women ( 45 vs. 32% in men) and is a major health problem across all the 22 countries. Only 18% of all the patients were found to reach a body mass index below 25 kg/m(2) whereas 53% were diagnosed with central obesity. Since their hospital discharge, only half of the obese patients reported to have followed the dietary recommendations and 48% reported engagement in more physical activity. Only 13% of the patients who were overweight at the time of the coronary event reached the target of >= 5% weight loss whereas 21% of them presented with a weight gain of 5% or more. Conclusion The prevalence of obesity is still increasing and reaching epidemic proportions in the high priority group of coronary patients all over Europe. Patients' awareness and current management of obesity seems inadequate. More intensive programs focusing on diet and especially physical activity are urgently required. Eur J Cardiovasc Prev Rehabil 17:447-454 (C) 2010 The European Society of Cardiology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available